GleamWall
中文EN

CAMP Camp4 Therapeutics Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1736730 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY39.9%
TTM net income YoY-126.8%
TTM EPS YoY-103.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,001.1%
Net margin-2,276.3%
FCF margin-496.4%
EBITDA margin-965.5%

Returns

ROE-146.1%
ROA-109.9%
ROIC (approx.)—
Asset turnover0.05x

Leverage & solvency

Liabilities / assets20.1%
Debt / equity0.00x
Current ratio6.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.21x
Accruals ratio-86.7%
Payout ratio—
Capex / revenue16.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.90M$1.78M$1.29M$348,000$795,000$1.50M$858,000$652,000
R&D expense$11.43M$10.82M$10.16M$8.36M$9.85M$10.34M$10.15M$10.00M
SG&A expense$4.49M$4.34M$4.21M$4.77M$4.60M$4.18M$3.81M$4.69M
Operating income-$14.03M-$13.38M-$13.07M-$12.78M-$13.65M-$13.03M-$13.10M-$14.03M
Income tax$0$0$0$0$0$0$0$0
Net income-$28.96M-$33.53M-$18.33M-$40.28M-$15.10M-$12.59M-$12.43M-$13.28M
EBITDA-$13.53M-$12.88M-$12.55M-$12.40M-$13.25M-$12.63M-$12.68M-$13.62M
EPS (basic)-0.37-0.58-0.32—-0.55-0.62-0.62—
EPS (diluted)-0.37-0.58-0.32—-0.55-0.62-0.62—
Dividends declared per share———0.000.000.000.00—
Weighted avg. shares (diluted)78.95M57.93M57.92M—27.27M20.16M20.15M—
Balance sheet
Cash & equivalents$124.52M$86.40M$99.21M$109.52M$76.88M$40.68M$50.95M$65.66M
Current assets$127.54M$90.03M$102.20M$114.09M$77.71M$41.09M$51.67M$66.38M
PP&E, net$1.68M$1.85M$1.93M$2.34M$2.90M$3.41M$3.60M$3.86M
Total assets$134.01M$93.43M$105.46M$117.81M$86.39M$51.27M$62.77M$78.31M
Current liabilities$19.86M$19.14M$16.62M$15.51M$7.90M$7.33M$6.44M$9.60M
Total liabilities$26.92M$94.12M$74.56M$70.10M$27.73M$11.29M$11.20M$15.16M
Shareholders' equity$107.09M-$693,000$30.90M$47.70M$58.67M$39.99M$51.57M$63.14M
Shares outstanding62.75M51.93M51.93M51.90M46.88M20.16M20.16M20.15M
Cash flow statement
Operating cash flow-$8.16M-$12.69M-$10.98M$6.29M-$11.22M-$10.34M-$14.29M-$11.29M
Capital expenditure$740,000$129,000$0$0$0$0$279,000$263,000
Free cash flow-$8.90M-$12.81M-$10.98M$6.29M-$11.22M-$10.34M-$14.56M-$11.55M
Investing cash flow-$740,000-$129,000$0$0$36,000$0-$279,000-$263,000
Financing cash flow$47.03M$4,000$57,000$28.59M$47.38M$72,000-$151,000$73.06M
Depreciation & amortization$500,000$500,000$520,000$372,000$400,000$400,000$421,000$418,000
Stock-based compensation$2.02M$1.93M$1.47M$1.15M$984,000$1.00M$861,000$797,000

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.